NCT06549504View on ClinicalTrials.gov

Bioequivalence Study of AG2202

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Bioequivalence Study
Interventions
DRUG

AG2202T

AG2202T Single-dose

DRUG

AG2202R

AG2202R Single-dose

Sponsors
All Listed Sponsors
lead

Ahn-Gook Pharmaceuticals Co.,Ltd

INDUSTRY

NCT06549504 - Bioequivalence Study of AG2202 | Biotech Hunter | Biotech Hunter